Cargando…
Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease
INTRODUCTION: Pathophysiology of diabetic kidney disease (DKD) is incompletely understood. We aim to elucidate metabolic abnormalities associated with DKD in type 2 diabetes mellitus (T2DM) by targeted plasma metabolomics. METHODS: A total of 126 T2DM participants with early DKD (urinary albumin-to-...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678636/ https://www.ncbi.nlm.nih.gov/pubmed/29142974 http://dx.doi.org/10.1016/j.ekir.2016.12.003 |
_version_ | 1783277478735773696 |
---|---|
author | Liu, Jian-Jun Ghosh, Sujoy Kovalik, Jean-Paul Ching, Jianhong Choi, Hyung Won Tavintharan, Subramaniam Ong, Choon Nam Sum, Chee Fang Summers, Scott A. Tai, E. Shyong Lim, Su Chi |
author_facet | Liu, Jian-Jun Ghosh, Sujoy Kovalik, Jean-Paul Ching, Jianhong Choi, Hyung Won Tavintharan, Subramaniam Ong, Choon Nam Sum, Chee Fang Summers, Scott A. Tai, E. Shyong Lim, Su Chi |
author_sort | Liu, Jian-Jun |
collection | PubMed |
description | INTRODUCTION: Pathophysiology of diabetic kidney disease (DKD) is incompletely understood. We aim to elucidate metabolic abnormalities associated with DKD in type 2 diabetes mellitus (T2DM) by targeted plasma metabolomics. METHODS: A total of 126 T2DM participants with early DKD (urinary albumin-to-creatinine ratio [ACR] 30−299 mg/g and eGFR ≥ 60 ml/min/1.73 m(2)), 154 overt DKD (ACR ≥ 300 mg/g or eGFR < 60 ml/min/1.73 m(2)), and 129 non-DKD T2DM controls (ACR < 30 mg/g and eGFR ≥ 60 ml/min/1.73 m(2)) were included in discovery study. Findings were subsequently validated in 149 T2DM with macroalbuminuria (ACR ≥ 300 mg/g) and 149 matched non-DKD T2DM controls. Plasma amino acid, acylcarnitine, Krebs cycle organic acid, and sphingolipids/ceramide levels were quantified by liquid chromatography−mass spectrometry and gas chromatography−mass spectrometry. RESULTS: Of 123 metabolites included in the data analysis, 24 differed significantly between DKD and controls in the same direction in both discovery and validation subpopulations. A number of short acylcarnitines including their dicarboxylic derivatives (C2−C6) were elevated in DKD, suggesting abnormalities in fatty acids and amino acids metabolic pathways. Five phosphatidylcholines were lower whereas 4 metabolites in the sphingomyelin−ceramide subfamily were higher in DKD. Principal component regression revealed that long-chain ceramides were independently associated with ACR but not eGFR. Conversely, essential amino acids catabolism and short dicarboxylacylcarnitine accumulation were associated with eGFR but not ACR. DISCUSSION: DKD is associated with altered fuel substrate use and remodeling of sphingolipid metabolism in T2DM with DKD. Associations of albuminuria and impaired filtration function with distinct metabolomic signatures suggest different pathophysiology underlying these 2 manifestations of DKD. |
format | Online Article Text |
id | pubmed-5678636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-56786362017-11-15 Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease Liu, Jian-Jun Ghosh, Sujoy Kovalik, Jean-Paul Ching, Jianhong Choi, Hyung Won Tavintharan, Subramaniam Ong, Choon Nam Sum, Chee Fang Summers, Scott A. Tai, E. Shyong Lim, Su Chi Kidney Int Rep Translational Research INTRODUCTION: Pathophysiology of diabetic kidney disease (DKD) is incompletely understood. We aim to elucidate metabolic abnormalities associated with DKD in type 2 diabetes mellitus (T2DM) by targeted plasma metabolomics. METHODS: A total of 126 T2DM participants with early DKD (urinary albumin-to-creatinine ratio [ACR] 30−299 mg/g and eGFR ≥ 60 ml/min/1.73 m(2)), 154 overt DKD (ACR ≥ 300 mg/g or eGFR < 60 ml/min/1.73 m(2)), and 129 non-DKD T2DM controls (ACR < 30 mg/g and eGFR ≥ 60 ml/min/1.73 m(2)) were included in discovery study. Findings were subsequently validated in 149 T2DM with macroalbuminuria (ACR ≥ 300 mg/g) and 149 matched non-DKD T2DM controls. Plasma amino acid, acylcarnitine, Krebs cycle organic acid, and sphingolipids/ceramide levels were quantified by liquid chromatography−mass spectrometry and gas chromatography−mass spectrometry. RESULTS: Of 123 metabolites included in the data analysis, 24 differed significantly between DKD and controls in the same direction in both discovery and validation subpopulations. A number of short acylcarnitines including their dicarboxylic derivatives (C2−C6) were elevated in DKD, suggesting abnormalities in fatty acids and amino acids metabolic pathways. Five phosphatidylcholines were lower whereas 4 metabolites in the sphingomyelin−ceramide subfamily were higher in DKD. Principal component regression revealed that long-chain ceramides were independently associated with ACR but not eGFR. Conversely, essential amino acids catabolism and short dicarboxylacylcarnitine accumulation were associated with eGFR but not ACR. DISCUSSION: DKD is associated with altered fuel substrate use and remodeling of sphingolipid metabolism in T2DM with DKD. Associations of albuminuria and impaired filtration function with distinct metabolomic signatures suggest different pathophysiology underlying these 2 manifestations of DKD. Elsevier 2016-12-16 /pmc/articles/PMC5678636/ /pubmed/29142974 http://dx.doi.org/10.1016/j.ekir.2016.12.003 Text en © 2016 International Society of Nephrology. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Translational Research Liu, Jian-Jun Ghosh, Sujoy Kovalik, Jean-Paul Ching, Jianhong Choi, Hyung Won Tavintharan, Subramaniam Ong, Choon Nam Sum, Chee Fang Summers, Scott A. Tai, E. Shyong Lim, Su Chi Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease |
title | Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease |
title_full | Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease |
title_fullStr | Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease |
title_full_unstemmed | Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease |
title_short | Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease |
title_sort | profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease |
topic | Translational Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678636/ https://www.ncbi.nlm.nih.gov/pubmed/29142974 http://dx.doi.org/10.1016/j.ekir.2016.12.003 |
work_keys_str_mv | AT liujianjun profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT ghoshsujoy profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT kovalikjeanpaul profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT chingjianhong profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT choihyungwon profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT tavintharansubramaniam profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT ongchoonnam profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT sumcheefang profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT summersscotta profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT taieshyong profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease AT limsuchi profilingofplasmametabolitessuggestsalteredmitochondrialfuelusageandremodelingofsphingolipidmetabolisminindividualswithtype2diabetesandkidneydisease |